title: Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study.
abstract: The aim of this study was retrospectively to assess the validity of the 2005 WHO-EORTC classification for primary cutaneous lymphomas (PCL) in a large cohort of patients of a single German skin cancer unit. All patients with PCLs consecutively visiting our hospital between January 1980 and December 2005 were included in a retrospective monocentre study, analysing their histological and clinical data. A total of 312 patients fulfilled the inclusion criteria for PCL. In 299 patients clinical information and paraffin material were sufficient for detailed classification. Of the 299 patients, 63% expressed a T-cell and 37% a B-cell phenotype. Mycosis fungoides was the entity with the highest frequency (30.9%), followed by primary cutaneous follicle centre lymphomas (16.9%) and lymphomatoid papulosis (15.9%). The mean follow-up period was 38.4 months. Five-year disease-specific survival was 80.5% for mycosis fungoides, 92.5% in primary cutaneous anaplastic large cell lymphoma, 100% in lymphomatoid papulosis, 98.1% in primary cutaneous follicle center lymphoma, 100% in primary cutaneous marginal zone lymphoma and 63.2% in diffuse large B-cell lymphoma, leg type. Our data are in line with the data collected by the WHO-EORTC. This is further evidence for the reliability of the WHO-EORTC classification and staging system.
authors.affiliation: Department of Dermatology, Fachklinik Hornheide, Munster, Germany. christian.hallermann@fachklinik-hornheide.de
authors.forename: Christian
authors.initials: C
authors.lastname: Hallermann
authors.forename: Christoph
authors.initials: C
authors.lastname: Niermann
authors.forename: Rudolf-Josef
authors.initials: RJ
authors.lastname: Fischer
authors.forename: Hans-Joachim
authors.initials: HJ
authors.lastname: Schulze
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D053208:Kaplan-Meier Estimate; D016393:Lymphoma, B-Cell / Q000145:classification / Q000175:diagnosis* / Q000401:mortality*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000401:mortality; D016410:Lymphoma, T-Cell, Cutaneous / Q000145:classification / Q000175:diagnosis* / Q000401:mortality*; D017731:Lymphomatoid Papulosis / Q000175:diagnosis / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000175:diagnosis / Q000401:mortality; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D015203:Reproducibility of Results; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012878:Skin Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000401:mortality*; D015996:Survival Rate; D013997:Time Factors